T-Bills Yield Up to 4.45%. Why Would Retirees Choose Dividend Stocks?24/7 Wall Street · 4 hr ago
Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancerGlobeNewsWire · 9 hr ago
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancerPRNewsWire · 10 hr ago
Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ moleculePRNewsWire · 16 hr ago
Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?The Motley Fool · 1 day ago
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancerGlobe News Wire · 1 day agoJohnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
| Date | Est. | Actual | |
|---|---|---|---|
| Oct 13, 2026 | $2.52 | $2.59 | Beat |
| Jul 15, 2026 | $2.85 | $2.90 | Beat |
| Apr 14, 2026 | $2.68 | $2.70 | Beat |
| Jan 21, 2026 | $2.46 | $2.46 | Beat |
| Oct 14, 2025 | $2.76 | $2.80 | Beat |
| Jul 16, 2025 | $2.68 | $2.77 | Beat |